Key facts
- Elion Therapeutics’s last known valuation is $163.0M (Aug 2025).
- It has raised $111.0M; the latest was Later Stage VC ($81.0M) in Aug 2025.
- Notable investors include Deerfield Management, Illinois Ventures, AMR Action Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Elion Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Elion Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Elion Therapeutics
Provider of clinical research and development services intended to treat systemic and life-threatening fungal infections. The company's services focus on the improvement of the Amphotericin B drug, enabling patients to receive a broad spectrum of antifungal drugs that are completely non-toxic in mammalian cells.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2018
- Employees
- 13
- Website
- eliontx.com/
- Ownership
- Privately Held (backing)
Elion Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elion Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elion Therapeutics in its N-PORT filings yet. We sweep new filings monthly.